Ortho Clinical Diagnostics, Inc. Announces Executive Leadership Additions as it Becomes an Independent, Stand Alone Company

Ortho Clinical Diagnostics, Inc. Announces Executive Leadership Additions as it Becomes an Independent, Stand Alone Company

Jul 8, 2014

Raritan, NJ, July 8, 2014 -- Today Ortho-Clinical Diagnostics, Inc. (OCD) unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group (NASDAQ: CG) from Johnson & Johnson. In his first act as OCD Chairman and Chief Executive Officer, Dr. Martin D. Madaus announced key appointments in finance, operations, legal and commercial to advance strategic sectors of the In Vitro Diagnostics (IVD) business.


“We have recruited top industry talent, recognized for their global diagnostics expertise, to build a revitalized, stand-alone company," said Dr. Madaus. “Under their leadership, OCD will be positioned to grow, enhance its industry-leading medical diagnostics products and services, and innovate with new, diagnostic solutions through targeted investment."


In February, The Carlyle Group announced that Dr. Madaus would lead OCD after the acquisition. Dr. Madaus has leveraged his business acumen and more than 25 years of experience in the diagnostics and life sciences industries to lay the groundwork for an independent OCD. Dr. Madaus and OCD will have a central focus on ensuring a seamless transition for customers.


Today, the company announced the following appointments:


Alex Socarras, Executive Vice President, Commercial

Mr. Socarras has strong commercial and general management experience in diagnostics in the U.S., Latin America and Europe. Prior to joining Ortho Clinical Diagnostics, Mr. Socarras was a senior vice president and CEO of healthcare in South West Europe at Siemens Healthcare. He also served as their vice president and region CEO of Latin America.


Robert Yates, Chief Operating Officer

Mr. Yates has extensive senior leadership experience delivering significant commercial and business successes in diagnostics and life sciences. He joins Ortho Clinical Diagnostics from EMD Millipore, where he served as president and CEO, leading the company through a period of outstanding growth. Prior to EMD Millipore, Mr. Yates was the head of life sciences, diagnostics business development and U.S. operations at Roche Diagnostics.


Jeffrey D. Capello, Chief Financial Officer

Mr. Capello has demonstrated a consistent record of improving the operational and financial health of global organizations across multiple industries. He was most recently Executive Vice President and Chief Financial Officer at Boston Scientific and has more than 29 years of experience in various roles in which he drove operational improvement and implemented strategies to drive value.


Michael Schlesinger, General Counsel

Mr. Schlesinger has extensive experience in corporate practice and M&A, and provided in-house counsel for a variety of venture-backed firms. As a former partner and corporate lawyer at Latham & Watkins, LLP, he has more than 25 years of experience representing numerous companies in a variety of business transactions including, acquisitions, sales, mergers, joint ventures and divestitures.


About Ortho-Clinical Diagnostics, Inc.

Ortho-Clinical Diagnostics, Inc. delivers high-quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho-Clinical Diagnostics, Inc. also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit www.orthoclinical.com.

© Ortho Clinical Diagnostics 2019. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. The availability of the products is subject to compliance with the regulatory requirements of each market.